A 0.25 mg injection pen of Novo Nordisk's weight-loss drug Wegovy is shown in this photo illustration in Oslo, Norway, September 1, 2023. REUTERS/Victoria Klesty/Illustration/File Photopublishes third-quarter results next week investors and analysts are hoping the company will clarify when limits on the supply of starter doses of its weight-loss drug Wegovy in the United States will cease.
It has also debuted the Wegovy injection in the UK and Germany in recent months, but availability is limited even though there is enormous pent-up demand. "However, after the positive recent earnings pre-announcement, I would not expect any negative manufacturing news from Novo in the short term," Manns said.The company has so far released scant details on its supply chain for Wegovy and Ozempic, but shareholders are increasingly trying to understand where the bottlenecks are.
Business Business Latest News, Business Business Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: Investingcom - 🏆 450. / 53 Read more »
Source: Reuters - 🏆 2. / 97 Read more »